L., Jornada, M
TRIUMPH-3 (NCT05882045) is a Phase 3, 80-week, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with severe obesity (Class 2 or Class 3), defined as BMI 35 kg/m 2 , and established cardiovascular disease
Hence, by reducing sdLDL, there is less substrate available to be oxidized, and thus liraglutide may help slow down or prevent the atherosclerotic processes at an early stage and prevent ischemic stroke [43]
But heres the good news: after she stopped the medication and maintained her weight for 3 months, her cycles regulated beautifully to every 28-30 daysthe most regular theyd been since she was a teenager
To arrive at their estimate, researchers combed through national registries, looking for people with the same characteristics as those in the SELECT trial and extrapolating that representative group to the population of the entire nation
Retrieved from Wilkinson, J
